Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade C 8.25 3.13% 0.25
AGLE closed up 7.96 percent on Tuesday, November 19, 2019, on 1.6 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AGLE trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 3.13%
Crossed Above 200 DMA Bullish 3.13%
Crossed Above 20 DMA Bullish 3.13%
Crossed Above 50 DMA Bullish 3.13%
MACD Bullish Centerline Cross Bullish 3.13%
Expansion Pivot Buy Setup Bullish Swing Setup 3.13%
Pocket Pivot Bullish Swing Setup 3.13%
Fell Below 200 DMA Bearish 11.34%
MACD Bearish Centerline Cross Bearish 11.34%
Expansion Pivot Sell Setup Bearish Swing Setup 11.34%

Older signals for AGLE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
Chemistry Biopharmaceutical Cancer Solid Tumors Organic Chemistry Inborn Errors Of Metabolism
Is AGLE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.45
52 Week Low 5.99
Average Volume 46,589
200-Day Moving Average 7.5654
50-Day Moving Average 7.9043
20-Day Moving Average 7.866
10-Day Moving Average 7.884
Average True Range 0.4199
ADX 13.04
+DI 17.4218
-DI 22.485
Chandelier Exit (Long, 3 ATRs ) 7.2403
Chandelier Exit (Short, 3 ATRs ) 8.4997
Upper Bollinger Band 8.4049
Lower Bollinger Band 7.3271
Percent B (%b) 0.62
BandWidth 13.702009
MACD Line 0.0076
MACD Signal Line 0.0315
MACD Histogram -0.0239
Fundamentals Value
Market Cap 131.62 Million
Num Shares 16.5 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -4.42
Price-to-Sales 15.71
Price-to-Book 1.22
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.04
Resistance 3 (R3) 8.94 8.51 8.86
Resistance 2 (R2) 8.51 8.24 8.55 8.80
Resistance 1 (R1) 8.25 8.08 8.38 8.35 8.75
Pivot Point 7.82 7.82 7.88 7.86 7.82
Support 1 (S1) 7.56 7.55 7.69 7.66 7.25
Support 2 (S2) 7.13 7.39 7.17 7.20
Support 3 (S3) 6.87 7.13 7.14
Support 4 (S4) 6.97